As part of the procedure, the trial will expand the age range of testing to children from 5 to 12 years old and adults 56 and older. The other, larger stage will test the vaccine’s effectiveness in volunteers 18 and older.
https://twitter.com/business/status/1263750966429523969
Recently, AstraZeneca received funding worth 1.2 billion dollars from United States for its efforts to get the immunization tested and ready for use.
Adults will be randomly chosen to receive one or two doses of an already licensed vaccine against meningococcus for comparison.